218 related articles for article (PubMed ID: 29463565)
1. An FGFR3/MYC positive feedback loop provides new opportunities for targeted therapies in bladder cancers.
Mahe M; Dufour F; Neyret-Kahn H; Moreno-Vega A; Beraud C; Shi M; Hamaidi I; Sanchez-Quiles V; Krucker C; Dorland-Galliot M; Chapeaublanc E; Nicolle R; Lang H; Pouponnot C; Massfelder T; Radvanyi F; Bernard-Pierrot I
EMBO Mol Med; 2018 Apr; 10(4):. PubMed ID: 29463565
[TBL] [Abstract][Full Text] [Related]
2. Dual targeting of FGFR3 and ERBB3 enhances the efficacy of FGFR inhibitors in FGFR3 fusion-driven bladder cancer.
Weickhardt AJ; Lau DK; Hodgson-Garms M; Lavis A; Jenkins LJ; Vukelic N; Ioannidis P; Luk IY; Mariadason JM
BMC Cancer; 2022 May; 22(1):478. PubMed ID: 35501832
[TBL] [Abstract][Full Text] [Related]
3. FGFR3 translocations in bladder cancer: differential sensitivity to HSP90 inhibition based on drug metabolism.
Acquaviva J; He S; Zhang C; Jimenez JP; Nagai M; Sang J; Sequeira M; Smith DL; Ogawa LS; Inoue T; Tatsuta N; Knowles MA; Bates RC; Proia DA
Mol Cancer Res; 2014 Jul; 12(7):1042-54. PubMed ID: 24784839
[TBL] [Abstract][Full Text] [Related]
4. Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice.
Qing J; Du X; Chen Y; Chan P; Li H; Wu P; Marsters S; Stawicki S; Tien J; Totpal K; Ross S; Stinson S; Dornan D; French D; Wang QR; Stephan JP; Wu Y; Wiesmann C; Ashkenazi A
J Clin Invest; 2009 May; 119(5):1216-29. PubMed ID: 19381019
[TBL] [Abstract][Full Text] [Related]
5. FGFR3 stimulates stearoyl CoA desaturase 1 activity to promote bladder tumor growth.
Du X; Wang QR; Chan E; Merchant M; Liu J; French D; Ashkenazi A; Qing J
Cancer Res; 2012 Nov; 72(22):5843-55. PubMed ID: 23019225
[TBL] [Abstract][Full Text] [Related]
6. ETV5 links the FGFR3 and Hippo signalling pathways in bladder cancer.
di Martino E; Alder O; Hurst CD; Knowles MA
Sci Rep; 2019 Apr; 9(1):5740. PubMed ID: 30952872
[TBL] [Abstract][Full Text] [Related]
7. Hypoxia regulates FGFR3 expression via HIF-1α and miR-100 and contributes to cell survival in non-muscle invasive bladder cancer.
Blick C; Ramachandran A; Wigfield S; McCormick R; Jubb A; Buffa FM; Turley H; Knowles MA; Cranston D; Catto J; Harris AL
Br J Cancer; 2013 Jul; 109(1):50-9. PubMed ID: 23778527
[TBL] [Abstract][Full Text] [Related]
8. Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer.
Juanpere N; Agell L; Lorenzo M; de Muga S; López-Vilaró L; Murillo R; Mojal S; Serrano S; Lorente JA; Lloreta J; Hernández S
Hum Pathol; 2012 Oct; 43(10):1573-82. PubMed ID: 22417847
[TBL] [Abstract][Full Text] [Related]
9. Dysregulated FGFR3 signaling alters the immune landscape in bladder cancer and presents therapeutic possibilities in an agent-based model.
Bergman DR; Wang Y; Trujillo E; Fernald AA; Li L; Pearson AT; Sweis RF; Jackson TL
Front Immunol; 2024; 15():1358019. PubMed ID: 38515743
[TBL] [Abstract][Full Text] [Related]
10. Loss of UTX/KDM6A and the activation of FGFR3 converge to regulate differentiation gene-expression programs in bladder cancer.
Barrows D; Feng L; Carroll TS; Allis CD
Proc Natl Acad Sci U S A; 2020 Oct; 117(41):25732-25741. PubMed ID: 32989154
[TBL] [Abstract][Full Text] [Related]
11. FGFR3-targeted mAb therapy for bladder cancer and multiple myeloma.
Hadari Y; Schlessinger J
J Clin Invest; 2009 May; 119(5):1077-9. PubMed ID: 19422094
[TBL] [Abstract][Full Text] [Related]
12. 1-tert-butyl-3-[6-(3,5-dimethoxy-phenyl)-2-(4-diethylamino-butylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea (PD173074), a selective tyrosine kinase inhibitor of fibroblast growth factor receptor-3 (FGFR3), inhibits cell proliferation of bladder cancer carrying the FGFR3 gene mutation along with up-regulation of p27/Kip1 and G1/G0 arrest.
Miyake M; Ishii M; Koyama N; Kawashima K; Kodama T; Anai S; Fujimoto K; Hirao Y; Sugano K
J Pharmacol Exp Ther; 2010 Mar; 332(3):795-802. PubMed ID: 19955487
[TBL] [Abstract][Full Text] [Related]
13. FGFR3 Down-Regulation is Involved in bacillus Calmette-Guérin Induced Bladder Tumor Growth Inhibition.
Langle YV; Belgorosky D; Prack McCormick B; Sahores A; Góngora A; Baldi A; Lanari C; Lamb C; Eiján AM
J Urol; 2016 Jan; 195(1):188-97. PubMed ID: 26144336
[TBL] [Abstract][Full Text] [Related]
14. Role of FGFR3 in bladder cancer: Treatment landscape and future challenges.
Ascione CM; Napolitano F; Esposito D; Servetto A; Belli S; Santaniello A; Scagliarini S; Crocetto F; Bianco R; Formisano L
Cancer Treat Rev; 2023 Apr; 115():102530. PubMed ID: 36898352
[TBL] [Abstract][Full Text] [Related]
15. Knockdown of long noncoding RNA FGFR3- AS1 induces cell proliferation inhibition, apoptosis and motility reduction in bladder cancer.
Liao X; Chen J; Liu Y; He A; Wu J; Cheng J; Zhang X; Lv Z; Wang F; Mei H
Cancer Biomark; 2018 Feb; 21(2):277-285. PubMed ID: 29226855
[TBL] [Abstract][Full Text] [Related]
16. Oncogenic FGFR3 gene fusions in bladder cancer.
Williams SV; Hurst CD; Knowles MA
Hum Mol Genet; 2013 Feb; 22(4):795-803. PubMed ID: 23175443
[TBL] [Abstract][Full Text] [Related]
17. Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo.
Lamont FR; Tomlinson DC; Cooper PA; Shnyder SD; Chester JD; Knowles MA
Br J Cancer; 2011 Jan; 104(1):75-82. PubMed ID: 21119661
[TBL] [Abstract][Full Text] [Related]
18. PIK3CA gene alterations in bladder cancer are frequent and associate with reduced recurrence in non-muscle invasive tumors.
Dueñas M; Martínez-Fernández M; García-Escudero R; Villacampa F; Marqués M; Saiz-Ladera C; Duarte J; Martínez V; Gómez MJ; Martín ML; Fernández M; Castellano D; Real FX; Rodriguez-Peralto JL; De La Rosa F; Paramio JM
Mol Carcinog; 2015 Jul; 54(7):566-76. PubMed ID: 24347284
[TBL] [Abstract][Full Text] [Related]
19. Daidzein exerts anti-tumor activity against bladder cancer cells via inhibition of FGFR3 pathway.
He Y; Wu X; Cao Y; Hou Y; Chen H; Wu L; Lu L; Zhu W; Gu Y
Neoplasma; 2016; 63(4):523-31. PubMed ID: 27268915
[TBL] [Abstract][Full Text] [Related]
20. FGFR3 Destabilizes PD-L1 via NEDD4 to Control T-cell-Mediated Bladder Cancer Immune Surveillance.
Jing W; Wang G; Cui Z; Xiong G; Jiang X; Li Y; Li W; Han B; Chen S; Shi B
Cancer Res; 2022 Jan; 82(1):114-129. PubMed ID: 34753771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]